Company
BiOrion is a Dutch clinical stage biopharmaceutical company engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. We are currently developing a PET-imaging diagnostic for NASH/liver fibrosis and a combined PET-imaging diagnostic and targeted radiotherapeutic for metastatic colon cancer. Our platform and drug development engine is based on proprietary PDGF-ß-receptor binding bicyclic peptides and VHH nanobodies.
Read moreTarget
Fibrotic tissue, as present in liver fibrosis and in mesenchymal type colon cancer stroma, is characterized by abundant myofibroblast-specific overexpression of the PDGF-ß-receptor. This over-expressed receptor allows myofibroblast-specific targeting and delivery of antifibrotic drugs, thereby leaving healthy tissues unaffected. After binding of BiOrion’s peptide-conjugate to the receptor, the complex is internalized and accumulated rapidly and, dependent on the payload, can exert its intracellular effect.
Read morePipeline
BiOrion has two active development programs. In the non-invasive diagnostic PET imaging program, radioactive Gallium-68 is conjugated to BOT501, the molecule containing the receptor-binding peptide. This PET imaging diagnostic is developed to identify patients with liver fibrosis or mesenchymal subtype colon cancer and to monitor therapy. In the radiotherapeutic program, radioactive Lutetium-177 is replacing radioactive Gallium-68 in BOT501. This radiotherapeutic is developed to treat patients with advanced metastatic mesenchymal subtype colon cancer.
Read moreSelective Targeting of Fibrotic stroma
allowing precise PET radio-imaging and radiotherapy of mesenchymal type colon cancer
News
BiOrion Technologies receives an EFRO TENDER VALORISATIE 2017 grant for its € 1.0 million cardiac fibrosis imaging program.
Groningen, The Netherlands, December 14, 2017 An EFRO TENDER VALORISATIE 2017 grant of a EUR 1.0 million cardiac …Read More »BiOrion Technologies, Zealand Pharma and Akademiska Sjukhuset Uppsala receive a EUROSTARS grant for their € 1.8 M fibrosis imaging program BONIFIB
September 26, 2017 Groningen, The Netherlands, September 26, 2017 The EUROSTARS grant of a EUR 1.8 million fibrosis imaging …Read More »BiOrion Technologies receives a VIA2016 grant for its targeted treatment program in fibrosis.
Groningen, The Netherlands, March 13, 2017 A VIA2016 grant of a EUR 50 thousand in fibrosis treatment is …Read More »
Events
no event
Partners
